Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to characterize the difference in prepubescent growth
velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with
triamcinolone acetonide (TAA) nasal spray (NASACORT® AQ 110 μg treatment group) or placebo
(NASACORT® AQ placebo group) for 12-months.
The secondary objectives were to compare the following in prepubertal participants treated
with TAA nasal spray versus placebo:
- the 24-hour urinary free cortisol levels and the cortisol/creatinine ratio (to measure
the Hypothalamic-Pituitary Adrenal [HPA] axis function)
- the rate of treatment-emergent-adverse-events (TEAE)
- global efficacy rated by the investigator and the participant separately
- the rate of use of rescue medication during the study